Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Mirragen Diabetic Foot Ulcer Study

NCT: NCT06598241 · RECRUITING

NCT IDNCT06598241
StatusRECRUITING
Start Date2024-09-20
Completion2026-12
SponsorThe University of Texas Health Science Center at San Antonio (OTHER)
First posted
Last updated

Brief Summary

This study is being done to collect data from treatment of patients who have diabetes with non-healing foot wounds and are being treated with a resorbable and biocompatible borate-based bioactive glass fiber matrix. A borate-based bioactive glass fiber matrix is used to cover the ulcer for wound management. The primary objective of this study is to evaluate the safety and efficacy of the borate-based bioactive glass fiber matrix in the treatment of diabetic foot ulcers in a real-world setting. The secondary objective is to evaluate the clinical and financial benefits in terms of quality of healing, pain, and treatment cost.

Frequently Asked Questions

What is Mirragen Diabetic Foot Ulcer Study?

Mirragen Diabetic Foot Ulcer Study is a clinical trial registered under NCT06598241. Current status: RECRUITING.

What is the status of NCT06598241?

The current status of NCT06598241 (Mirragen Diabetic Foot Ulcer Study) is: RECRUITING.

When did Mirragen Diabetic Foot Ulcer Study start?

Mirragen Diabetic Foot Ulcer Study started on 2024-09-20.

Related Devices

K161067Mirragen Advanced Wound Matrix, 4x4”, Mirragen Advanced Wound Matrix, 2x2”, Mirragen Advanced Wound Matrix, 1x6”Engineered Tissue Solutions, LLC

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑